Cardiometabolic Outcomes with Dapagliflozin After Myocardial Infarction by Baseline Ejection Fraction: DAPA-MI
Authors' conclusion
Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, although there was no impact on the composite of cardiovascular death or hospitalization for HF.
Study context
- Population
- Patients after acute myocardial infarction (MI) without established diabetes or heart failure (HF), categorised by left ventricular ejection fraction (LVEF) at randomisation (<50% or ≥50%)with LVEF data, ≥1 dose
- Participants
- 3,751 patients
- Comparison
- Dapagliflozin 10 mg once daily vs placebo
- Primary endpoint
- Hierarchical composite (win ratio) of death, HF hospitalisation, non-fatal MI, AF/flutter, T2DM, NYHA class at last visit and body weight decrease ≥5%
Methodological detailssubgroup analysis by baseline LVEF
- Subgroup analysis by baseline LVEF
Primary result
As reported in the abstract
Primary hierarchical composite, by baseline LVEF
Dapagliflozin vs PlaceboWin ratio (95% CI)P value
LVEF <50% (n = 2913, 77.7%)
1.38(1.21–1.57)
P < 0.001LVEF ≥50% (n = 838, 22.3%)
1.32(1.00–1.73)
P = 0.048Secondary outcomes
| Outcome | Win ratio (95% CI) | P value | |
|---|---|---|---|
| Primary composite, sensitivity analysis excluding LVEF <30% | 1.40 (1.22–1.61) | P < 0.001 | |
| 0.512Win ratio (log scale) |
Secondary outcomes by baseline LVEF
- No significant interactions between baseline LVEF and any secondary outcomes
Original publication
Cardiometabolic Outcomes with Dapagliflozin After Myocardial Infarction by Baseline Ejection Fraction: DAPA-MI. ESC Heart Fail. Published 16 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →